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Summary 
BACKGROUND: Extracorporeal photopheresis (ECP) has 
been reported to be safe and the ultimate treatment op-
tion in lung transplant recipients with chronic lung allo-
graft dysfunction (CLAD), the main overall cause of mor-
tality in lung transplant recipients. However, ECP is not 
reimbursed in selected health jurisdictions, and reim-
bursement by health insurance providers is a major is-
sue. In Switzerland, ECP is not recognised by the health 
authorities as a therapy option for CLAD; thus by the end 
of 2014, ECP had to be stopped in the majority of adult 
lung transplant recipients cared for at the University 
Hospital Zurich because of lack of continuous funding. 
OBJECTIVE: To describe the outcome of lung transplant 
recipients after forced cessation of ECP treatment. 
METHOD: We retrospectively analysed outcome of 12 
lung transplant recipients undergoing ECP for different 
phenotypes of CLAD (bronchiolitis obliterans syndrome, 
restrictive allograft syndrome) at our centre followed-up 
for 12 months after forced cessation of ECP. 
RESULTS: Within the 12 months after treatment cessa-
tion, seven patients (58%) died with a median survival of 
207 days (range 6–365 days). Lung function (FEV1, 
forced expiratory volume in 1 second) declined signifi-
cantly 6 months after ECP cessation (p = 0.003). 
CONCLUSION: Our data support the role of ECP as valu-
able treatment option in lung transplant recipients with 
CLAD. 
Key words: lung transplantation; chronic lung allograft 
dysfunction; extracorporeal photopheresis 
Introduction 
Chronic lung allograft dysfunction (CLAD) is the main 
cause of death in lung transplant recipients [1]. The 
mechanisms of CLAD are not completely understood. 
Different CLAD “phenotypes” have been described, such 
as bronchiolitis obliterans syndrome (BOS) and restric-
tive allograft syndrome (RAS) [2]. Bronchiolitis obliter-
ans syndrome is the main cause of death in lung trans-
plant recipients after the first post-transplant year; it is 
observed in approximately 50% of patients by 5 years af-
ter transplantation and >75% after 10 years [3]. Early di-
agnosis and initiation of treatment is considered to be of 
vital importance to slow progression, preserve lung func-
tion and maintain quality of life. The initial management 
of BOS consists of augmentation of immunosuppression 
and immunomodulation using macrolide antibiotics. The 
role of statins and leukotriene receptor antagonists for the 
prevention of CLAD progression is less clear [4]. 
Extracorporeal photopheresis (ECP) is considered as sec-
ond-line treatment for lung transplant recipients develop-
ing CLAD whose condition deteriorates following aug-
mentation of immunosuppression and use of macrolide 
antibiotics [2]. Recently published work suggested that 
ECP may be able to stabilise or slow lung function loss 
without an increased infection risk and also to improve 
survival in patients with BOS without causing significant 
adverse effects [2, 5, 6]. The exact mechanisms of ECP 
are elusive but it is thought to induce apoptosis of lym-
phocytes and to generate regulatory T cells, which mod-
ulate transplant immune rejection [7–9]. At our centre, 
ECP treatment has been performed since 1997 for various 
indications including CLAD [5]. 
From the autumn of 2014, financial reimbursement for 
ECP was progressively withdrawn by health insurance 
providers, despite repeated appeals in each individual 
 case, and by the end of 2014 ECP had to be stopped for 
the vast majority of adult lung transplant recipients at our 
centre. We assessed clinical outcome of these patients 
over a period of 1 year after cessation of ECP treatment, 
including lung allograft function and patient survival. 
Methods 
Study design 
We performed a retrospective patient data collection and 
analysis, using electronic charts. We included all lung 
transplant recipients who had received ECP treatment for 
BOS or RAS and in whom ECP treatment was stopped 
because of withdrawal of reimbursement by health insur-
ance providers by the end of December 2014. Data from 
12 months before cessation of ECP up to 12 months 
thereafter was collected. Patients who survived for 12 
months after ECP was stopped, and patients who were 
granted reimbursement and continued ECP were fol-
lowed up until 30 November 2016. Analysis includes 
baseline patient demographics, CLAD phenotype and 
lung function. Autopsy reports were reviewed where 
available. 
The local Ethics Committee approved the study (KEK # 
2016-00534). 
Extracorporeal photopheresis 
ECP was performed in collaboration with the Department 
of Dermatology, University Hospital of Zurich. Since 
1997, a standardised protocol had been used in Zurich for 
ECP, with cycles (1 cycle = 2 days) every 4 weeks. This 
protocol was changed in 2013 for to be comparable to the 
protocol used by the Hannover and Vienna group: an in-
duction phase was introduced, with ECP cycles every 2 
weeks for 3 months and 4 weekly thereafter [2, 10]. As 
previously described, extracorporeal photopheresis was 
performed using the UVARXTS system (Therakos, Ex-
ton, PA) approved by the US Food and Drugs Admin-
istration. Briefly, leukapheresis in the UVAR system is 
followed by photoactivation with methoxsalen (8-meth-
oxypsoralen) and UVA irradiation, and subsequent rein-
fusion of irradiated cells over 3 to 4 hours. During ECP, 
peripheral blood mononuclear cells are separated from 
the whole blood in a Latham centrifuge at 2700 g. 
Uvadex® methoxsalen solution (Therakos) is added di-
rectly into the buffy coat bag before extracorporeal irra-
diation with UVA (1–2 J/m2), reducing systemic methox-
salen toxicity. The number of blood mononuclear cells 
exposed to methoxsalen and UVA during each procedure 
is usually 2 to 5% of the total circulating white cells [5]. 
Spirometry was performed at each ECP and outpatient 
attendance according to ATS/ERS guidelines [11]. For 
each month the highest available FEV1 value (forced ex-
pired volume in 1 second) and FVC (forced vital capac-
ity) were tabulated. All patients were diagnosed and 
graded for CLAD according to a recently published prac-
tice guideline consensus document [12]. 
Patients 
On 31 August 2014, 15 lung transplant recipients were 
undergoing ECP treatment for BOS and RAS (fig. 1). 
From September to December 2014, ECP treatment had 
to be stopped in 12 patients, despite repeated appeal in 
each individual case. Demographic information for these 
patients is presented in table 1. Seven patients were fe-
male. The median age was 49 years (range 30–70 years). 
Underlying diagnosis leading to bilateral lung transplan-
tation included COPD (n = 4), cystic fibrosis (n = 3), sar-
coidosis (n = 2), idiopathic pulmonary fibrosis (n = 1), 
pulmonary arterial hypertension (n = 1) and diffuse inter-
stitial lung disease (n = 1). The patients were on ECP 
treatment for BOS 2 (n = 3), BOS 3 (n = 7) and RAS (n 
= 2). Most patients (n = 9) were under dual immunosup-
pression with prednisone/ciclosporin or prednisone/tac-
rolimus, three patients had additional treatment with my-
cophenolate mofetil (n = 3). 
 
 
 
Figure 1: ECP follow-up and survival. On 31 August 2014, 15 
patients were undergoing ECP treatment; 12 were stopped 
between September and December 2014, 3 patients contin-
ued and survived the follow-up period. Of the 12 patients 
stopping ECP, 10 were treated for BOS and 2 for RAS. 5 BOS 
patients and 2 RAS patients died (death rate 58%). BOS = 
bronchiolitis obliterans syndrome; ECP = extracorporeal pho-
topheresis; RAS = restrictive allograft syndrome. 
 
 
 
  
 Table 1: Demographics for all patients (survival reported up to 12 months), for those who died within 12 months following 
ECP cessation and those who survived a minimum 12 months after ECP was stopped (survival reported until 30 November 
2016). 
  Total  
(n = 12) 
Deaths  
(n = 7) 
Survivals  
(n = 5) 
Sex Male (%) 5 (42) 2 3 
Female (%) 7 (58) 5 2 
Median age (range), years   49 (30–70) 50 (37–70) 40 (30–59) 
Underlying disease COPD (%) 4 (34) 4 0 
Cystic fibrosis (%) 3 (26) 0 3 
Sarcoidosis (%) 2 (16) 1 1 
IPF (%) 1 (8) 1 0 
PAH (%) 1 (8) 0 1 
Diffuse interstitial lung 
disease (%) 
1 (8) 1 0 
Phenotype BOS (%) 10 (84) 5 5 
RAS (%) 2 (16) 2 0 
Median number of ECP cy-
cles (range) 
 44 (8–142) 33 (8–129) 72 (12–142) 
Median time under ECP 
treatment (range) 
 1001 (168–6054) 898 (168–4568) 2716 (260–
5054) 
Death (%)  7 (58)  3 (60) 
Median survival time 
(range), days 
 207 (6–365) 156 (6–334) 699 (525–675) 
Cause of death Infection (%) 3 (43)  0 
Progression (%) 3 (43)  2 
Cancer (%) 1 (14)  0 
Other (%)   1 
BOS = bronchiolitis obliterans syndrome; COPD = chronic obstructive pulmonary disease; ECP = extracorporeal photophere-
sis; IPF = idiopathic pulmonary fibrosis; PAH = pulmonary arterial hypertension; RAS = restrictive allograft syndrome 
 
Statistical analysis 
Data are reported as medians with ranges. Continuous 
variables were compared using the Mann-Whitney-U-
test. Two-sided t-tests and Wilcoxon signed rank tests 
were used to compare variables before and after ECP 
treatment cessation. Kaplan-Meier estimates of survival 
were calculated. For all analyses p-values <0.05 were 
considered statistically significant. 
Results 
From September to December 2014, ECP treatment had 
to be stopped in 12 patients. At the time of ECP cessation 
the 12 patients had received a median of 44 ECP cycles 
(8–142) with a median duration of ECP treatment of 1001 
days (168–5054 days). Four patients started ECP treat-
ment less than 12 months before cessation of ECP, three 
8 months and one 10 months earlier. As shown in figures 
1 and 2, seven of the 12 patients (58%) died within 12 
months after ending ECP treatment (58%). Median sur-
vival time after cessation of ECP was 207 days (range 6–
365 days). Three patients died of CLAD progression, 
three as a result of infection, including one patient who 
died (from infection) 6 days after ECP cessation, and one 
(14%) of extra-pulmonary cancer. All patients who died 
from infection had concomitant CLAD progression. Pa-
tients did not receive any additional treatment (rabbit an-
tithymocyte globulin, alemtuzimab, total body irradia-
tion) potentially contributing to infection. Autopsy re-
ports were available in four patients only, all of which 
confirmed the clinically suspected cause of death. Sur-
vival time did not significantly differ between different 
CLAD phenotypes, sex, age and underlying disease. 
At baseline, median FEV1 was 920 ml (610–3870 ml) 
(table 2). Prior to ECP cessation, lung function was stable 
in all patients, with a median FEV1 loss of 13 ml/month 
(8–110 ml/month); lung function values were available 
in all patients for each month. After ECP cessation, FEV1 
declined rapidly (median FEV1 of 800 ml, range 520–
3720 ml; p = 0.003) within 6 months. The median FEV1 
loss per month, measured at the end of the 12-month ob-
servation period (or last available value before death), 
 was 17 ml (range 6–163 ml). There was no significant 
difference in monthly lung function loss before and after 
ECP cessation. As a result of their impaired condition, 
monthly lung function testing results were unavailable in 
some of patients (median FEV1 measurements 5 per 12 
months, range 0–12). 
Of the five patients who survived the 12 months follow-
ing ECP cessation, two died from CLAD progression 585 
and 675 days after ECP was stopped, one patient died 
from complications following repeat lung transplantation 
525 days later. Within the 12 months following ECP ces-
sation they showed a median FEV1 loss of 13 ml/month 
(range 0–980 ml/month). 
For comparison, of the three CLAD patients who were 
granted reimbursement for continued ECP (one of them 
after a direct patient appeal to the insurance provider), 
two remained stable without any lung function decline 
until the 30 November 2016; one developed CLAD pro-
gression starting in the summer of 2016 and was still 
alive on 30 November 2016. 
Immunosuppressive treatment was not changed after 
ECP cessation. Most patients (n = 9) were under dual im-
munosuppression with prednisone/ciclosporin or predni-
sone/tacrolimus; three patients had additional treatment 
with mycophenolate mofetil. Prednisone doses did not 
have to be augmented after ECP cessation. 
 
 
 
Figure 2: Kaplan-Meier plot of survival time. Seven of 12 pa-
tients (58%) died within the 12 months of follow-up. Median 
survival time was 207 days (range 6–365). 
 
Table 2: Clinical outcome indicators. 
 ECP After ECP p-value 
Median FEV1 (range), ml 920 (610–3660) 800 (520–3720) 0.003 
Median FEV1 decline per 
month (range), ml 
13 (8–110) 17 (6–163) NS 
ECP = extracorporeal photopheresis; FEV1 = forced expiratory volume in 1 second; NS = not significant 
 
Discussion 
In this retrospective analysis, we investigated the effects 
of ECP cessation in a unique cohort of lung transplant 
recipients. Our data show a decline of lung function and 
a high mortality rate within 12 months after ECP cessa-
tion. This large study analysed clinical outcome in a co-
hort of lung transplant recipients after forced ECP cessa-
tion, emphasising the potential benefits of ECP for main-
taining already impaired allograft function in patients 
with CLAD. 
In 1995, ECP was first described as a treatment for severe 
acute lung allograft rejection following infection [13]. 
Later, ECP had also been administered, by our group and 
others, to patients with BOS, who showed stabilisation of 
lung function [5, 14, 15]. The only prospective study to 
date showed stabilisation of lung function and signifi-
cantly longer survival of patients with CLAD under ECP 
treatment [10]. In all published data to date, ECP has 
shown to be a safe treatment without significant adverse 
effects. Our study analysed the effect of ECP cessation 
for non-medical reasons (reimbursement issues with 
Swiss healthcare providers) in lung transplant recipients 
with CLAD. 
We observed a monthly FEV1 loss of 13 ml during ECP 
treatment, which is in line with other reports [2, 5]. 
Whereas no increase of monthly lung functional decline 
could be observed after ECP cessation, we found a de-
cline in median FEV1 (after 6 months or last FEV1 value 
available). These findings imply that the calculated 
monthly FEV1 loss after ECP cessation is likely under-
estimated, probably because monthly lung function data 
could not be obtained from all patients,. 
Following ECP cessation, a very high mortality rate of 
58% was observed within 12 months in our lung trans-
plant recipient cohort (median survival time 207 days, 
range 3–365 days), which is in strong contrast to the fact 
that most patients had received long-term ECP (median 
of 44 cycles, median duration of ECP 1001 days). Death 
was mainly due to infection and progression of CLAD, 
confirming the findings of other studies [2, 5, 10]. No dif-
ference in survival time between different CLAD pheno-
types was revealed. The high mortality rate after ECP 
cessation raises the question of whether ECP withdrawal 
triggers an immunogenic response that, in turn, results in 
further CLAD progression, but this remains speculative 
at this time. 
 Of our total cohort, three CLAD patients were able to 
continue ECP after multiple appeals to the health insur-
ance providers. Although the small group of patients is 
not suited to serve as a well-matched control group, it is 
of note that all three patients remained clinically stable 
and maintained their lung function while continuing 
ECP. All three patients are currently still alive with a me-
dian patient survival of 15 years (range 13–20). Overall 
survival of patients who received lung transplants at our 
centre in Zurich has recently been reported to be 84%, 
71% and 67% at 1, 3 and 5 years, respectively [16]. Lung 
function remained stable in two patients with no decline 
until November 2016, and one patient recently developed 
CLAD progression. 
Limitations of our retrospective study include the small 
sample size and limited lung function data after cessation 
of ECP as a result of the patients’ severely impaired con-
dition. Moreover, the overall sample size was too small 
to distinguish the effects of ECP cessation on on outcome 
and survival in the different CLAD phenotypes. In con-
clusion, we document a high mortality rate of lung trans-
plant recipients within 1 year after forced ECP cessation, 
emphasising the important role of ECP for preservation 
of lung function and prolonged survival in patients with 
CLAD. 
Since 2016, ECP has newly been covered by health in-
surance (OKP-Leistungskatalog) for treatment of CLAD. 
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